

Reference Number: FOI202324/401
From: Commercial
Date: 06 December 2023
Subject: Trust spend on unlicensed medication

- Q1** Please provide the following information you have pertaining to NHS Trust unlicensed medicine expenditure.
What is the total value of spend by your NHS Trust on unlicensed medication (i.e. Special Order, Drug Tariff Special Order, Part VIID Drug Tariff Special Order) that have a BNF liquid formulation (e.g. liquid, solution, suspension)? Please provide this information on a volume and value basis for the following years (please fill in the tables below).
Note: Value of spend to mean either net ingredient cost or actual cost. Please state which you have used below. Actual cost would be the total cost to NHS commissioners whereas NIC is the cost at list price excluding VAT.

A1 Total Value:

Type	Total spend / cost on liquid unlicensed products procured		
	Apr-20 to Mar-21	Apr-21 to Mar-22	Apr-22 to Mar-23
Special Order	£21,669.37	£11,303.94	£10,874.49
Drug Tariff Special Order	0	0	0
Part VIID Drug Tariff Special Order	0	0	0
Other Special	0	0	0

Total Volume:

Type	Total spend / cost on liquid unlicensed products procured		
	Apr-20 to Mar-21	Apr-21 to Mar-22	Apr-22 to Mar-23
Special Order	582770 mL	143540 mL	228335 mL
Drug Tariff Special Order	0	0	0
Part VIID Drug Tariff Special Order	0	0	0
Other Special	0	0	0

- Q2** Do you outsource the manufacturing of liquid unlicensed products?

A2 Yes

Q3 If no to question 2 (use of outsourcing providers), what proportion of the products that you manufacture in-house are aseptically compounded rather than terminally sterilised?

A3 Not Applicable as per A2

Q4 If yes to question 2 (use of outsourcing providers), what is the total value of spend by provider? Please provide this information for the following years (*please fill in the tables below*). Note: If more than 10 providers are used, please only detail spend with the top 10.

A4 Information exempt under Section 43 - Due to the potential damage to commercial interests of the current suppliers as release of this information and any other unique pricing likely to be requested for disclosure would allow other competitors a significant competitive advantage and thus harm the commercial interests of our current suppliers.